Positive topline results from an open-label trial of tapinarof cream combination

On December 13, 2023, positive topline results were announced from the single-center, open-label clinical trial of tapinarof 1% cream, an aryl hydrocarbon receptor agonist,¹ in combination with injectable biologics for the treatment of adult patients with plaque psoriasis to achieve National Psoriasis Foundation treat-to-target goal.²

Overall, 30 patients with ≥3% body surface area plaque psoriasis who had been on stable biologic therapy for ≥26 weeks received tapinarof cream as an additional therapy, receiving a single dose of tapinarof daily for a 12-week period.

Results²

At Week 12, treatment with tapinarof was stopped, with outcomes measured from baseline until Week 16.

• 52% of patients achieved body surface area of ≤1%
• Patients achieved a 75% reduction in Psoriasis Area and Severity Index score at Week 12, which was maintained up to Week 16
• At Week 12, lesions on genital areas had cleared on all patients (n = 3)
• No severe adverse events or new safety issues were reported

Conclusion

Based on this topline data, tapinarof 1% cream in combination with injectable biologics demonstrated positive outcomes for adult patients with plaque psoriasis in accordance with the National Psoriasis Foundation’s treat-to-target goal.